昊海生科2025年营收、净利双降

Core Viewpoint - Haohai Biological Technology (688366) reported a decline in both revenue and net profit for the fiscal year 2025, attributed to increased competition and a decrease in domestic cataract surgery volume [1] Group 1: Financial Performance - The company achieved an operating revenue of approximately 2.473 billion yuan, a year-on-year decrease of 8.33% [1] - The net profit attributable to shareholders was about 251 million yuan, reflecting a year-on-year decline of 40.3% [1] Group 2: Market Conditions - The domestic cataract surgery total in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [1] - Increased competition in the market, particularly from domestic brands offering significant cost advantages, has pressured the sales of imported products [1] Group 3: Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for the goodwill of its subsidiary Shenzhen New Industry [1] - Additionally, the U.S. subsidiary Aaren Scientific Inc. has indicated signs of impairment for its intangible assets, leading to a provision of about 24.98 million yuan [2]